The Progressive

The Progressive
Contributor since: 2013
Regarding your comment about Sphere and Glassware, I think the landscape of the cloud space is about to shift in a big way depending on which one of these giants can incorporate/embed Glassware into their cloud offerings first.
It would appear from this Dell World tweet from yesterday, that Dell is the first in line to build a significant relationship with Sphere 3D. (Dell also has already partnered with Sphere in the healthcare space with the Dell DRIVE partnership)
If you look closely, you will see the Glassware 2.0 logo on the Dell server - could this mean Sphere's Glassware 2.0 will be offered as an OEM feature on Dell enterprise servers?? Of course it is possible that Sphere simply set up their Dell World display using Dell servers, but still I would think to put the Glassware 2.0 Logo on a Dell server would have to have Dell's blessing at the least!
Great insights Retired Pharma, I appreciate your responses and your sharing your obvious depth of knowledge and experience in this arena, thank you!
Has anyone heard of a company called Sphere 3D? (OTCQX:SPIHF)
In my opinion, they are about to make compatibility issues of software platforms across different Operating systems obsolete.
Hi inside man,
I think this video of the CEO presentation at the cantech investment conference will give you a good start on info on Sphere. I believe they will be the big breakout cloud tech company of 2014. Good luck.
IMO, Sphere 3D (OTCQX:SPIHF) is one step ahead with their impressive Glassware 2.0 technology. They are about to break through into the cloud industry in a huge way and I believe they will soon be uplisting to Nasdaq. Their proprietary tech allows anyone to use any program in its full native form with full features on any device, with no latency, no matter what OS they are using. It is really very impressive stuff and the market cap for this company is very low and they are flying very much under the radar - but not for long!
Another superb article, well researched and thorough. SYN certainly seems to have significant potential considering the small market cap at this time.
Nice write up!
Great article that has the correct perspective on the Xbox One. This really is a multifaceted entertainment hub with still excellent gaming capabilities. Just being able to take those multiple tv, surround sound, and cable box remotes and set them aside in favor of simple voice commands is a fantastic feature to have, one that I suspect consumers will embrace more and more as time goes on. The road to monetization of this tech, and the multiple pathways for MSFT to generate revenue from all of this TV/video integration is going to be robust. There is alot to be said for products that can simplify our lives, Xbox one can be one of those products. Great write up QTR, long term I also believe this is a big, big winner for MSFT.
Great article, I thoroughly enjoyed reading it. Nice job!
Very interesting, informative, and intriguing article. There certainly seems to be potential here worth looking into further. Nicely written
Excellent article calling out the many parallels and similarities between CTIX and PCYC a few years back. Very well written and easy to follow. Nice job by the author. I have been saying for a while now that I believe the CTIX chart will look like the PCYC chart does today in short time.
Excellent article, very well written with lots of good info and insight. The author has certainly made a compelling case here. If I were not tied up with another emerging biotech, I would certainly consider taking a strong position here after further DD.
Great read, nice job. Look forward to your future contributions.
A very encouraging development this morning and confirmation that my speculation in my article was correct. Cellceutix this morning announced an agreement with MD Anderson in Houston to perform a variety of studies with Kevetrin. Very encouraging that the planned studies seem to be pretty comprehensive and well thought out. I beleive this relationship will pay big dividends for CTIX down the road, and another world renowned cancer center funding studies for Kevetrin certainly speaks to the potential that MD Anderson sees in Kevetrin.
Here is the Press Release from this morning :
Cellceutix Signs Material Transfer Agreement for Research of Kevetrin in Lymphoma and Multiple Myeloma Cancers With Major Cancer Center

Beverly, MA -- 06/26/13 -- Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company has signed a Material Transfer Agreement (MTA) with The University of Texas M.D. Anderson Cancer Center (“MD Anderson”). Per the MTA, Cellceutix will provide MD Anderson with Kevetrin, the Company’s novel anti-cancer drug candidate, for laboratory research of Kevetrin as a potential new treatment for Lymphoma and Multiple Myeloma.

MD Anderson intends to utilize in vivo and in vitro methods to research specific pathways, gene expression, mechanism of action and apoptotic activity of Kevetrin in a range of concentrations and time points in both mutant and wild-type p53 Myeloma and Lymphoma cell lines. Research is also planned to evaluate Kevetrin against models of Multiple Myeloma cell lines that are resistant to bortezomib, lenalidomide and other FDA-approved chemotherapies. Additional studies will be conducted evaluating the anti-tumor activity of Kevetrin when used as a combination therapy with several FDA-approved drugs. MD Anderson will provide funding for these studies of Kevetrin defined by the MTA.

“This is another significant development in our advancement of Kevetrin. We are thrilled by the collaboration and MD Anderson’s interest in researching Kevetrin as a potential new drug for Multiple Myeloma and Lymphoma,” said Leo Ehrlich, Chief Executive Officer at Cellceutix. “Currently moving through clinical trials for solid tumors at Harvard’s Dana-Farber Cancer Center, Kevetrin being evaluated for blood cancers at MD Anderson puts our novel drug in the hands of innovative and experienced scientists at two of the most prestigious cancer research centers in the world, bar none. MD Anderson has defined a robust course of study that will provide invaluable insight to the anti-tumor activity of Kevetrin that will be used to plan for additional clinical trials as we continue to execute our strategy to aim Kevetrin at a broad spectrum of cancer lines.”
Logistics, For a good grasp on the potential value of kevetrin, i like this article posted by ajackson a while back. His opinion covers many relevant points and the revenue potential of the cancers kevetrin is being tested on.
Hello olsondavid and me39,
Thank you for voicing your thoughts here, i appreciate and respect all opinions, as I would hope others would do for me even if they strongly disagree.. I understand that my opinions about Kevetrin are about as bullish as can be, and it certainly is not a view I expect everyone to have. However, I do want to clarify that although my thoughts are very direct and optimistic, I genuinely believe in the science and the management here. I am a long term investor in Cellceutix, and certainly not interested in any shady attempts at quick profits or "pump and dump" as its called. I am holding this stock because I believe it will be very successful once Kevetrin is fully proven with solid human clinical trial data.
Fortunately for all of us, whether you are the biggest bull on CTIX as I am, or the biggest skeptic as some may be, the good news is that the human trials at Harvard have been dosing for going into 7 months now, and the team at Dana Farber will be doing a poster presentation at the ASCO conference at the end of this month. I do believe at this point and shortly after the facts and the trial data will draw a clear picture of just how Kevetrin is performing. I wish you both the best of luck in whatever choices of investments you pursue. - TP
There are many eyes on the Kevetrin trial. Targeting P53 and successfully activating this gene with low toxicity would without a doubt be a breakthrough into the next gen of cancer treatment. Will be very interesting to see trial data and results as the current phase 1 human trial at Harvard now enters its 7th month of dosing advanced stage 4 patients.
This article is more relevant today than ever. We are awaiting the next Phase I clinical trial update from Harvard. The next step is to approve a 4th cohort and elevate dosing. So far, so good with the trial as no Dose Limiting Toxicities have been reported.
There is also a steady buzz speculating about the CEO's recent comments that Dana Farber has decided to initiate P21 biomarker testing so early in the trial. This could potentially signal at a very early stage that Kevetrin is activating P53 in humans as it did in animal studies. Clearly Harvard would not waste it's time testing for P21 unless they believed they had some compelling data to justify it.
Things are about to get very interesting for Cellceutix and it's shareholders. ASCO, the super bowl of oncology, is right around the corner and Cellceutix will be center stage with a poster presentation. Perhaps a big announcement declaring efficacy will follow shortly after?
Great interview and article, loaded with lots of very promising and compelling info for current and potential shareholders. This company has so much going on simultaneously that it is almost hard to wrap your head around, but this article and interview did just that.
Great job Karin, thank you for sharing!
Excellent and timely article, very nicely written! There is a flurry of activity going on right now with Kevetrin trials and studies, but investors should not lose sight of Prurisol and the fact that a trial announcement start date is imminent, and these trial results will comevery rapidly. With the confirmation of proof of concept could come a partnership/licensing deal that will bring significant revenue to Cellceutix as it marches onward in clinical trials at Harvard for Kevetrin.
For those investors willing to build a position now with the stock holding at a mere $2 per share, the risk to reward ratio is in my opinion probably the most compelling in the biotech industry right now.
This could change rapidly, as I anticipate any number of catalysts could send the stock price soaring in the short term:
- a Kevetrin clinical trial update and bloodwork analysis
- the announcement of a clinical trial agreement with the premiere cancer in the SouthWest
- potential announcement of an agreement with the National Cancer Institute and a potential SPORE grant to fund further research and trials
- an announcement on planned presentation of Kevetrin data at ASCO
- Prurisol clinical trial start date and location
- Prurisol manufacturing and production completed along with sending product to the FDA for approval
As you can see, any number of imminent events and developments have the potential to send this undervalued stock up significantly. With the share price holding very steady at $2 with little to no selling, a strong, long shareholder base will ensure that price movement going up will be substantial with any good news.
Great article, well thought through and logical outlook, a pleasure to read a well researched and accurate article. Nice job!
Very comprehensive and informative wrtie up on the immense potential of kevetrin, great job AJ
Well written and informative article, nice job Chemist.
Agree here, this was a huge miss on the part of the NYTimes. Excellent article with thoughtful speculation and detailed info, really a great read for those seeking to find out about the potential of kevetrin.
Thank you, I felt it would be helpful to lay out the different key elements of the company strategy in a Q&A session. For a small biotech like this, it is almost hard to wrap your head around all the world class institutions and big name connections that are coalescing around the company, as kevetrin and prurisol both advance onwards to potentially improve the lives of millions of people.
A well thought through and well written article, I agree the potential of this company is incredible, and offers one of the better risk to reward ratios out ere. Nice job!
I agree with bio this is a fantastic write up providing clear, concise, and specific info on why this is a great finance deal for the company. More importantly it builds even more confidence in the ongoing trials as CTIX would not get such a favorable deal if things weren't progressing well on the trial front. Great write up, thanks for sharing your thoughts!